Switch theme
Sign up to access all valuation multiples
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company’s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
2013
88
LTM Revenue n/a
LTM EBITDA -$129M
$295M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Solid Biosciences has a last 12-month revenue of n/a and a last 12-month EBITDA of -$129M.
In the most recent fiscal year, Solid Biosciences achieved revenue of n/a and an EBITDA of -$102M.
Solid Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Solid Biosciences valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $8.1M | n/a | n/a | n/a | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$96.9M | -$102M | -$125M | -$129M | XXX |
| EBITDA Margin | -1197% | -Infinity% | -Infinity% | -Infinity% | XXX |
| Net Profit | -$72.2M | -$86.0M | -$96.0M | XXX | XXX |
| Net Margin | -892% | -Infinity% | -Infinity% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Solid Biosciences's stock price is $6.
Solid Biosciences has current market cap of $441M, and EV of $295M.
See Solid Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $295M | $441M | XXX | XXX | XXX | XXX | $-2.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Solid Biosciences has market cap of $441M and EV of $295M.
Solid Biosciences's trades at n/a LTM EV/Revenue multiple, and -2.3x LTM EBITDA.
Analysts estimate Solid Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Solid Biosciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $295M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | XXX | XXX |
| P/E | -3.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSolid Biosciences's NTM/LTM revenue growth is n/a
Solid Biosciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Solid Biosciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Solid Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Solid Biosciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Solid Biosciences acquired XXX companies to date.
Last acquisition by Solid Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Solid Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Solid Biosciences founded? | Solid Biosciences was founded in 2013. |
| Where is Solid Biosciences headquartered? | Solid Biosciences is headquartered in United States of America. |
| How many employees does Solid Biosciences have? | As of today, Solid Biosciences has 88 employees. |
| Who is the CEO of Solid Biosciences? | Solid Biosciences's CEO is Mr. Alexander G. Cumbo. |
| Is Solid Biosciences publicy listed? | Yes, Solid Biosciences is a public company listed on NAS. |
| What is the stock symbol of Solid Biosciences? | Solid Biosciences trades under SLDB ticker. |
| When did Solid Biosciences go public? | Solid Biosciences went public in 2018. |
| Who are competitors of Solid Biosciences? | Similar companies to Solid Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Solid Biosciences? | Solid Biosciences's current market cap is $441M |
| What is the current EBITDA of Solid Biosciences? | Solid Biosciences's last 12-month EBITDA is -$129M. |
| What is the current EV/EBITDA multiple of Solid Biosciences? | Current EBITDA multiple of Solid Biosciences is -2.3x. |
| Is Solid Biosciences profitable? | Yes, Solid Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
